Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Migraine Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| H-21048416 | N/A |
Unknown status |
Post-Traumatic Headache |
2023-12-31 |
2024-06-04 |
Primary Endpoints|Treatments|Trial Status |
|
| H22038923 | N/A |
Completed |
Migraine Disorders |
2023-08-04 |
2023-12-05 |
Primary Endpoints|Start Date|Treatments |
|
| H19065735 | N/A |
Completed |
Headache|Migraine Disorders |
2021-03-19 |
2021-07-15 |
Primary Endpoints |
|
| H-17011569 | N/A |
Unknown status |
Cluster Headache |
2020-01-01 |
2021-01-06 |
Primary Endpoints |
|
| MigRosExperiment | N/A |
Completed |
Migraine without Aura|Migraine Disorders|Flushing|Headache Disorders|Migraine with Aura |
2019-12-07 |
2020-05-29 |
Patient Enrollment|Primary Endpoints |
|
| H-4-2014-103 | N/A |
Completed |
Migraine without Aura|Migraine Disorders|Headache Disorders|Migraine with Aura |
2016-04-01 |
2019-03-20 |
Treatments |
|
| H-2-2013-043 | N/A |
Completed |
Migraine with Aura|Migraine without Aura|Migraine Disorders |
2014-11-01 |
2019-03-20 |
Treatments |
|
| KA-20060087 | N/A |
Completed |
Headache Disorders|Migraine with Aura|Migraine without Aura|Migraine Disorders |
2007-11-01 |
2019-03-21 |
Treatments |
|
| NCT02542605 | P1 |
Completed |
Migraine Disorders |
2017-09-28 |
2019-06-04 |
Patient Enrollment|Treatments |